In a study with patients with laBCC previously treated with an HHI,

Clinically meaningful tumor reduction observed after treatment with LIBTAYO

Patient responses

The objective response rate in Study 1620 was 29% in patients with laBCC and median DOR was not reached (range: 2.1-21.4+ months)1

These are examples from the 23% of patients who had a PR in Study 1620.1 Individual patient responses may vary.
Right
Auricular
Lesion
History2
  • 79-year-old man
  • Locally advanced BCC
  • Disease progression on prior vismodegib
Right
Cranial
Lesion
History2
  • 66-year-old man
  • Locally advanced BCC
  • Intolerance on prior vismodegib
Right Nasal
Cavity
Lesion
History2
  • 77-year-old woman
  • Locally advanced BCC
  • Disease progression on prior vismodegib
Nasal cavity lesion, screening image, after 36 weeks, after 44 weeks, after 92 weeks
This is an example from the 6% of patients who had a CR in Study 1620.1
Individual patient responses may vary.
Left
Periorbital
Lesion
History2
  • 49-year-old man
  • Locally advanced BCC
  • Disease progression on prior vismodegib
Periorbital lesion, screening image, after 9 weeks, after 45 weeks, after 68 weeks
  • Plus sign (+) denotes ongoing at last assessment.1
  • BCC=basal cell carcinoma; CR=complete response; HHI=hedgehog inhibitor; ICR=independent central review; laBCC=locally advanced BCC; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; WHO=World Health Organization.

References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc.